Modified mutant collagenase and its use in fat melting and in scar reduction
A Clostridium histolyticum collagenase ColH (Glu451Asp) melts adipose tissue when injected into selected regions of the body. This protein product melts fat pads effectively in fat rat experiments, with very little side effects. Very little hemorrhage was observed. We also invent a new version of ColH mutant by linking a peptide motif CKGGRAKDC-G (varying from 2 to 6 Gs) (SEQ ID NO: 2) in front of ColH (Glu451Asp) (called topical ColH-FM), which can target to white fat vasculature. By combining with novel transdermal technology (such as Hydroxysome technology), we develop a topical protein cream that can melt fat. This product can be used as cellulite cream and for chemical liposuction. This topical ColH-FM can also be injected into adipose tissue as a replacement for liposuction or as an adjunct method with liposuction. Since raise scar is formed by overgrowth of collagen, our topical ColH-FM cream is shown to have application in scar reduction.
1. A method for reducing the amount of adipose tissue at selected locations in the body comprising:
administering an effective amount of a modified single mutant collagenase ColH-FM- or a peptide that includes the sequence of ColH-FM to adipose tissue or a subject in need of reducing the amount of adipose tissue,
wherein the ColH-FM is a Clostridium histolyticum collagenase ColH having a single substitution corresponding to Glu451Asp of the wild-type ColH and a peptide motif of CKGGRAKDC-G(x) at the N-terminal of said ColH, wherein x is 2 to 6 (SEQ ID NO: 2).
2. A method for reducing or removing lipomas comprising:
administering an effective amount of a modified single mutant collagenase ColH-FM- or a peptide that includes the sequence of ColH-FM to a lipoma or a subject in need of reducing or removing lipomas,
wherein the ColH-FM is a Clostridium histolyticum collagenase ColH having a single substitution corresponding to Glu451Asp of the wild-type ColH and a peptide motif of CKGGRAKDC-G(x) at the N-terminal of said ColH, wherein x is 2 to 6 (SEQ ID NO: 2).
3. A method for reducing scars comprising:
administering an effective amount of a modified single mutant collagenase ColH-FM- or a peptide that includes the sequence of ColH-FM to scar tissue or a subject in need of reducing scars,
wherein the ColH-FM is a Clostridium histolyticum collagenase ColH having a single substitution corresponding to Glu451Asp of the wild-type ColH and a peptide motif of CKGGRAKDC-G(x) at the N-terminal of said ColH, wherein x is 2 to 6 (SEQ ID NO: 2).
4. The method of claim 1 , wherein the ColH-FM is injected or topically applied.
5. The method of claim 3 , wherein the ColH-FM is injected or topically applied.
6. The method of claim 4 , wherein the ColH-FM is topically applied using a transdermal delivery system in a formulation of cream, serum, or liquid form.
7. The method of claim 5 , wherein the ColH-FM is topically applied using a transdermal delivery system in a formulation of cream, serum, or liquid form.
8. The method of claim 1 , wherein the administration step comprises administrating the collagenase ColH-FM in a form of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ColH-FM.
9. The method of claim 8 , wherein the carrier is at least one selected from the group consisting of a saline solution, an aqueous dextran solution, and an aqueous hetastarch solution.
10. The method of claim 1 , wherein the collagenase ColH-FM has the sequence of SEQ ID NO: 1.
11. The method of claim 2 , wherein the administration step comprises administrating the collagenase ColH-FM in a form of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ColH-FM.
12. The method of claim 11 , wherein the carrier is at least one selected from the group consisting of a saline solution, an aqueous dextran solution, and an aqueous hetastarch solution.
13. The method of claim 2 , wherein the collagenase ColH-FM has the sequence of SEQ ID NO: 1.
14. The method of claim 3 , wherein the administration step comprises administrating the collagenase ColH-FM in form of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ColH-FM.
15. The method of claim 14 , wherein the carrier is at least one selected from the group consisting of a saline solution, an aqueous dextran solution, and an aqueous hetastarch solution.
16. The method of claim 3 , wherein the collagenase ColH-FM has the sequence of SEQ ID NO: 1.